HUA MEDICINE (SHANGHAI) LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.52 HKD | +0.66% |
|
-8.43% | -22.84% |
| Mar. 28 | Hua Medicine Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Hua Medicine Ltd. Appoints Yi Zhang as Executive Director with Effect from January 1, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Hua Medicine is a China-based company principally engaged in the drug development business. The Company is mainly engaged in the development of an oral drug, Dorzagliatin, or HMS5552, for the treatment of Type 2 diabetes. The Company mainly operates its business in the domestic and overseas markets.
Calendar
2024-06-26
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.396
CNY
Average target price
3.072
CNY
Spread / Average Target
+120.12%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.84% | 189M | |
| -3.39% | 102B | |
| +2.61% | 96.84B | |
| -1.02% | 21.48B | |
| -18.14% | 20.82B | |
| -6.87% | 18.6B | |
| -40.70% | 16.81B | |
| -26.89% | 13.78B | |
| +1.12% | 13.4B | |
| +22.25% | 11.06B |
- Stock Market
- Equities
- 2552 Stock
- News Hua Medicine (Shanghai) Ltd.
- Hua Medicine Shanghai : Diabetes Drug Completes Phase III Trial
